Clinical effect of Secuchiumab in the Treatment of Psoriasis

Abstract

Psoriasis is a chronic and recurrent skin condition triggered by the immune system, with a relatively high prevalence. The primary clinical manifestation of this condition is the appearance of red and swollen patches of skin covered with silvery scales, often accompanied by itching and a feeling of tightness. In addition to skin symptoms, psoriasis patients frequently experience systemic conditions such as arthritis and heart disease. Recent research has shown a strong link between psoriasis and metabolic syndrome. The main symptoms of metabolic syndrome include hypertension, high blood sugar, elevated cholesterol levels, and abdominal obesity. These issues not only increase the risk of cardiovascular diseases but may also exacerbate the severity of psoriasis. Traditional treatments for psoriasis have included topical medications, phototherapy, and symptomatic relief therapies, with methotrexate being a common drug. While these conventional methods can partially improve the skin condition of psoriasis patients with metabolic syndrome, they are not effective at modulating immune system function or correcting metabolic imbalances. As our understanding of the pathophysiology of psoriasis deepens, biologic therapies have increasingly become a research focus. Secukinumab, a monoclonal antibody targeting interleukin-23, inhibits specific inflammatory pathways and offers a new, potentially more effective treatment option for psoriasis patients with metabolic syndrome.